Know Cancer

or
forgot password

Mayo Clinic Validation of the MiCK Assay


N/A
18 Years
N/A
Open (Enrolling)
Both
Mesothelioma, Small Cell Lung Cancer, NSCLC

Thank you

Trial Information

Mayo Clinic Validation of the MiCK Assay


This study will be conducted in two phases.

During the Feasibility Phase, specimens from any tumor will be sent to the central DiaTech
MiCK assay laboratory to determine the ease of sample acquisition, processing, transport,
and assay interpretation.

Once DiaTech has completed analyses for the feasibility phase specimens and has confirmed
that the sample acquisition, processing, transport, and assay interpretation are
appropriate, we will proceed with the Demonstration Phase.

During the Mesothelioma Demonstration Phase, 20 mesothelioma samples will be assayed and the
results will be correlated with prior patient therapy, performance status, and extent of
disease.


Inclusion Criteria:



- 20 subjects diagnosed with mesothelioma and 10 diagnosed with any malignancy.

Exclusion Criteria:

- patients that a sample cannot obtained for testing.

Type of Study:

Observational [Patient Registry]

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Complete response and survival

Outcome Time Frame:

1 year

Safety Issue:

No

Principal Investigator

Mary Karaus

Investigator Role:

Study Director

Investigator Affiliation:

Mayo Clinic

Authority:

United States: Mayo Clinic IRB

Study ID:

MAYO1000

NCT ID:

NCT01770665

Start Date:

June 2012

Completion Date:

March 2014

Related Keywords:

  • Mesothelioma, Small Cell Lung Cancer, NSCLC
  • Lung Neoplasms
  • Mesothelioma
  • Small Cell Lung Carcinoma

Name

Location

Mayo Validation Support Services 3050 Superior Drive NWRochester, Minnesota  55901